Added to YB: 2026-01-29
Pitch date: 2026-01-27
IDXG [bullish]
Interpace Biosciences, Inc.
+2.86%
current return
Author Info
Clinical Edge researches and shares thesis-driven ideas on potential healthcare multibaggers. Sign up for the newsletter.
Company Info
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States.
Market Cap
$52.3M
Pitch Price
$1.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
9.51
P/E
17.42
EV/Sales
1.27
Sector
Health Care Providers and Services
Category
value
Interpace Biosciences: Thesis Confirmed ($IDXG)
IDXG (update): Thyroid diagnostics co up 30% since Dec profile. 2025 revenue $38-39M, thyroid segment +21% growth to $34-35M, guiding $40M 2026 (+16%). Profitable w/ positive EBITDA. PE sponsors converted preferred to common (84% ownership), paid off all debt. Seeking Nasdaq uplisting 2026. 1.2x forward sales vs peers at 7x+.
Read full article (4 min)